Trial · NCT01712399
Results by group124
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 124
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Mavrilimumab 100 mg | TEAEs | 288 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Mavrilimumab 100 mg | TESAEs | 46 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) | Mavrilimumab 100 mg | Anaemia | 8 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) | Mavrilimumab 100 mg | Eosinophilia | 1 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) | Mavrilimumab 100 mg | Iron deficiency anaemia | 2 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) | Mavrilimumab 100 mg | Leukocytosis | 1 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) | Mavrilimumab 100 mg | Leukopenia | 1 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) | Mavrilimumab 100 mg | Lymphadenopathy | 1 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) | Mavrilimumab 100 mg | Neutropenia | 2 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) | Mavrilimumab 100 mg | Spontaneous haematoma | 1 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) | Mavrilimumab 100 mg | Alanine aminotransferase increased | 8 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) | Mavrilimumab 100 mg | Aspartate aminotransferase increased | 6 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) | Mavrilimumab 100 mg | Blood creatinine increased | 1 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) | Mavrilimumab 100 mg | Blood glucose increased | 1 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) | Mavrilimumab 100 mg | Blood pressure increased | 3 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) | Mavrilimumab 100 mg | C-reactive protein increased | 1 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) | Mavrilimumab 100 mg | Chest X-ray abnormal | 1 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) | Mavrilimumab 100 mg | Forced vital capacity abnormal | 1 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) | Mavrilimumab 100 mg | Gamma-glutamyltransferase increased | 2 | Participants | |
| Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) | Mavrilimumab 100 mg | Hepatic enzyme increased | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01712399/results